Clinical Research Directory
Browse clinical research sites, groups, and studies.
MitoQ to Improve Vascular Funciton in Preeclampsia
Sponsor: Medical College of Wisconsin
Summary
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Official title: MitoQ (Mitoquinol Mesylate) to Ameliorate Vascular Function in Preeclampsia: a Novel Approach
Key Details
Gender
FEMALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-12-01
Completion Date
2027-09-30
Last Updated
2025-11-14
Healthy Volunteers
No
Conditions
Interventions
Mitoquinol Mesylate
Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
Placebo
Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.